Anzeige
Mehr »
Login
Montag, 13.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
News des Tages Löst FDA-Zulassung jetzt Kaufrausch aus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 940602 ISIN: NL0000009538 Ticker-Symbol: PHI1 
Tradegate
13.07.20
14:16 Uhr
42,750 Euro
+0,920
+2,20 %
1-Jahres-Chart
KONINKLIJKE PHILIPS NV Chart 1 Jahr
5-Tage-Chart
KONINKLIJKE PHILIPS NV 5-Tage-Chart
RealtimeGeldBriefZeit
42,79042,80014:42
42,79042,80014:42
GlobeNewswire (Europe)
297 Leser
Artikel bewerten:
(1)

Royal Philips: Philips launches HealthSuite Clinical Trial Accelerator to help life science organizations run more flexible, patient-centric clinical trials

May 19, 2020

Amsterdam, the Netherlands -Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making.

Philips HealthSuite is an integrated, modular set of standards-based capabilities that support the development of digital propositions across the health continuum, encompassing HIPAA compliant, secure cloud capabilities. Clinical Trial Accelerator enables patient-centric trials at home, managing the collection of data while providing the security and compliance expected from both patients and life science organizations.

Life science organizations face continued pressure to run more efficient, cost-effective clinical trials. Empowering patients and making it easier for them to stay connected and contribute to a trial can have a significant impact on compliance rates and overall success. At the same time, collecting data and identifying actionable insights while ensuring the security and compliance of patient information is key. Clinical Trial Accelerator is designed to address these challenges, helping life science organizations reach their goals faster and supporting greater flexibility in trial design.

"Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with Clinical Trial Accelerator we have created a tailored set of capabilities to support life science organizations," said Dale Wiggins, General Manager for the HealthSuite digital platform at Philips. "Our innovative, flexible cloud platform leverages our global healthcare capabilities and is supported by our compliance, security and interoperability expertise."

Tailored capabilities to accelerate clinical trials
Other HealthSuite capabilities include an AI Analytics Workbench for enhanced decision making and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, as well as the HealthSuite Clinical Data Lake, a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

These HealthSuitecapabilities offer companies cloud-based services and technical tools that meet privacy, security and regulatory requirements that they can use to develop and run a new generation of connected healthcare applications. Unlike other digital platforms, HealthSuite is purpose-built to solve the complex challenges of healthcare, featuring capabilities to manage device data, collect personal and health data, store and share data securely, analyze data, build and deploy AI models, and create solutions on the cloud.

In addition, these HealthSuite capabilities power a wide range of both Philips and 3rd party connected healthcare applications in areas including image-guided therapy, sleep and respiratory care, ophthalmology, telehealth and self-medication. For 3rd party collaborations, Philips is the provider of the relevant cloud-based healthcare IT infrastructure and is not involved in the commercialization of the products and services of these companies. More information on Philips HealthSuite can be found at www.philips.com/healthsuite.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

About Royal Philips

Royal Philips.

Attachments

  • Philips Care Orchestrator for sleep and respiratory therapy (https://ml-eu.globenewswire.com/Resource/Download/7ac0d2b4-d690-4ece-91d8-4a94c626f117)
  • Philips HealthSuite logo (https://ml-eu.globenewswire.com/Resource/Download/ba93351a-af9f-4e79-b8d3-1351a1c53230)
PHILIPS-Aktie jetzt für 0€ handeln - auf Smartbroker.de
© 2020 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.